‘Dupilumab,’ moderate-to-severe eczema therapy, lands in Korea

Published: 2018-04-04 16:27:00
Updated: 2018-04-04 13:15:22

‘Dupilumab,’ a moderate-to-severe eczema treatment for adults, will land in the Korean market.

As of 30 March, the Ministry of Food and Drug Safety(MFDS) approved Sanofi-Aventis Korea’s ‘Dupixent Prefilled Inj 300mg(generic name: dupilumab)’ as new drug.

‘Dupilumab’ is a targeted biologic thera...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.